Otsuka announces 2011 fourth quarter U.S. net sales figures of ABILIFY® (58KB)
Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets" (267KB)
Otsuka Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders (51KB)
(58KB)
